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Abstract 
Bone homeostasis is maintained by the balance between osteoclasts which degrade bone and 
osteoblasts, which form new bone.  When the activity of either of these cells is dysregulated, bone 
loss can ensue, leading to osteoporosis, a disease characterized by low bone mass and an increase in 
bone fragility and risk of fracture.  The activity of osteoclasts and osteoblasts is regulated by local 
and systemic factors, as well as by key signaling proteins expressed in these cells.  Kalirin is a 
novel GTP-exchange factor protein that plays a role in signaling pathways leading to cytoskeletal 
remodeling and dendritic spine formation in neurons, but its function in other cells is 
unknown.  Western blotting and real time PCR confirmed that Kalirin is expressed in osteoclasts 
and osteoblasts, suggesting it may play a role in regulating bone cell function and bone mass.  We 
used micro-CT to examine the bone phenotype of 14 week old female mice lacking Kalirin in all 
tissues (Kal-KO).   Kal-KO mice exhibited a 40% lower trabecular bone volume in the distal femur 
compared to wild-type (WT) mice (n=9/group, p<0.05).  We next quantified osteoclasts in 
histological sections by counting multinucleated cells expressing tartrate-resistant acid phosphatase 
(TRAP), a marker of mature osteoclasts.  We found 48% higher osteoclast surface/bone surface in 
trabecular bone of Kal-KO mice, compared to WT mice (n=6/group, p<0.05).  Osteoclast 
differentiation is controlled by osteoblasts, which secrete receptor activator of NF-kB ligand 
(RANKL), macrophage colony stimulating factor (MCSF) and osteoprotegerin (OPG), a decoy 
receptor for RANKL.  We examined if Kalirin could regulate osteoclast differentiation in 
vitro.  Osteoclasts were generated from the bone marrow of WT or Kal-KO mice by incubation 
with RANKL and MCSF for 7 days, and TRAP+ multinucleated cells were counted.  Consistent 
with our in vivo studies, osteoclast number was significantly higher in cultures from Kal-KO mice, 
compared to WT mice.  We next examined if Kalirin altered the ratio of secreted RANKL and OPG 
secreted by osteoblasts.  Osteoblasts were generated from the calvaria of 2 day old neonates and the 
level of secreted RANKL and OPG in conditioned media was quantified by ELISA.  Consistent 
with increased osteoclast differentiation, we found a higher RANKL/OPG ratio in conditioned 
media from Kal-KO osteoblasts, compared to WT cells.  These data confirm a role for Kalirin in the 
regulation of trabecular bone mass through effects in both osteoclasts and osteoblasts. 
  
  
 
